There is theoretical and observational data suggesting SSRI antidepressants might be helpful for Covid. Fluvoxamine (brand name Luvox) is an SSRI with strong Sigma1R activation, which may also be relevant.

A recent small preregistered RCT of Fluvoxamine reported a very positive effect, as did a not-yet-published observational report. A larger trial is underway by the same investigators as the first one.

Summaries of the case for Fluvoxamine are available here and here from the director of a nonprofit which partially funded both trials. A writeup from WIRED magazine can be found here.

This question asks:

Before 2022, will Fluvoxamine receive authorization for treatment of Covid by the United States FDA before the end of the pandemic?

This question resolves positively if, before 2022, the US FDA grants an emergency use authorization for the use of Fluvoxamine as a treatment for Covid.

In the unlikely event of full authorisation being granted without emergency use authorisation, this question will resolve positive.

If an EUA is granted but later revoked, this would not change the outcome of the question.

This resolves positively even if the authorization is limited to certain classes of higher-risk patients, as was the case for Bamlanivimab, and even if other governmental agencies (eg. NIH) do not recommend it as standard of care.